Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10606MR)

This product GTTS-WQ10606MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ10606MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3625MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ2228MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aVWF81
GTTS-WQ15941MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ10531MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ13464MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PRS-343
GTTS-WQ2903MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG827
GTTS-WQ9916MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA KB-003
GTTS-WQ13155MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-04383119
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW